Yanna Liu

Dr. Yanna Liu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
MYMingjie Yao
Mingjie Yao
LWLeijie Wang
Leijie Wang
JWJianwen Wang
Jianwen Wang
YLYanna Liu
Yanna Liu
SLShuhong Liu
Shuhong Liu
FLFengmin Lu
Fengmin Lu
Background. There is lack of reliable serum biomarkers to reflect the severity of liver necroinflammation for those who suffer autoimmune liver diseases (AILDs). In this study, a previously established patient cohort was used to explore the potential of serum Golgi protein 73 (GP73) as a noninvasive marker of AILD-related liver necroinflammation. Methods. Serum GP73 concentration was measured in a retrospective cohort of 168 AILD patients, which included 74 patients with autoimmune hepatitis (AIH) and 94 with primary biliary cholangitis (PBC) who had undergone liver biopsy. Spearman’s correlation and multivariate analysis were used to evaluate the relationship between serum GP73 and liver necroinflammation. A receiver operating characteristic curve was constructed to evaluate the value of GP73 for the prediction of moderate or severe liver necroinflammation. The diagnostic value of serum GP73 was also compared with that of alkaline phosphatase (ALP) in patients with PBC. Histologically, immunohistochemical analysis was performed to assess hepatic GP73 expression. Results. Both the serum level and hepatic tissue expression of GP73 protein were aberrantly elevated and correlated well with the severity of necroinflammation in both AIH ( , ) and PBC ( , ) patients. The results here suggested that serum GP73 could be an independent biomarker to reflect the severity of liver necroinflammation. The AUROCs for GP73 to predict moderate necroinflammation (≥G2) and severe necroinflammation (≥G3) in patients with AIH were 0.828 and 0.832, respectively. Moreover, the AUROCs of serum GP73 for the identification of moderate necroinflammation (≥G2) ( , ) and severe necroinflammation (≥G3) ( , ) were superior to those of ALP (≥G2: , and ≥G3: ,

26 July 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
YWYuchen Wang
Yuchen Wang
SYSusha Yan
Susha Yan
YLYanna Liu
Yanna Liu
ZYZiyan Yan
Ziyan Yan
WDWenfeng Deng
Wenfeng Deng
YMYun Miao
Yun Miao
The classical lytic infection theory along with large T-mediated oncogenesis cannot explain the BK polyomavirus (BKPyV)-associated tumor secondary to BKPyV-associated nephropathy (BKVAN), viremia/DNAemia, and viruria after renal transplantation. This study performed virome capture sequencing and pathological examination on regularly collected urine sediment and peripheral blood samples, and BKVAN and tumor biopsy tissues of 20 patients with BKPyV-associated diseases of different stages. In the early non-cancerous stages, well-amplified integration sites were visualized by in situ PCR, simultaneously with BKPyV inclusion bodies and capsid protein expression. The integration intensity, the proportion of microhomology-mediated end joint integration, and host PARP-1 and POLQ gene expression levels increased with disease progression. Furthermore, multi-omics analysis was performed on BKPyV-associated urothelial carcinoma tissues, identifying tandem-like structures of BKPyV integration by long-read genome sequencing. The carcinogenicity of BKPyV integration was proven to disturb host gene expression and increase viral oncoprotein expression. Fallible DNA double-strand break repair pathways were significantly activated in the parenchyma of BKPyV-associated tumors. Olaparib showed an antitumor activity dose-response effect in the tumor organoids without BRCA1/2 genes mutation. In conclusion, the dynamic viral integration patterns actively participate in the progression of BKPyV-associated diseases, and thus could be a potential target for disease monitoring and intervention.

29 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
XQXiangjun Qian
Xiangjun Qian
YLYanna Liu
Yanna Liu
FWFengping Wu
Fengping Wu
SZSiyu Zhang
Siyu Zhang
JGJiao Gong
Jiao Gong
FLFengmin Lu
Fengmin Lu
Background and aims: Factors associated with abnormally elevated alpha-fetoprotein (AFP) in hepatitis B virus (HBV)-infected patients remain to be studied. We aimed to identify factors associated with elevated serum AFP in patients with non-hepatocellular carcinoma (HCC) and early-stage HCC and their influences on the performance of AFP for detecting early-stage HCC. Methods: This multicenter, retrospective study was conducted in 4401 patients with chronic HBV infection, including 3680 patients with non-HCC and 721 patients with early-stage HCC. Factors associated with elevated AFP were analyzed. Diagnostic performance of AFP for early-stage HCC were compared among groups through area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. Results: When analyzed by multivariate logistic regression, antiviral therapy was negatively associated with elevated AFP, while hepatitis B e antigen (HBeAg) and aspartate aminotransferase (AST) > 1× upper limit of normal (ULN) were positively associated with elevated AFP both in patients with non-HCC and early-stage HCC (all p < 0.05). The AUCs of AFP for detecting early-stage HCC in patients with antiviral therapy, HBV DNA (−), alanine aminotransferase (ALT) ≤ 1× ULN, and AST ≤ 1× ULN were significantly higher compared to those in non-antiviral therapy, HBV DNA (+), ALT > 1× ULN, and AST > 1× ULN groups, respectively. When categorizing patients into AST ≤ 1× ULN and > 1× ULN, AFP achieved the highest AUCs in patients with AST ≤ 1× ULN regardless of antiviral treatment (AUCs = 0.813 and 0.806, respectively). Furthermore, there were considerable differences in the cut-off values of AFP in detecting early-stage HCC in different subgroups when applying similar sensitivity and specificity. Conclusions: Antiviral therapy and serum AST might be used to help judge and select the specific cut-off values of serum AFP for HCC surveillance in different at-risk populations.

1 March 2016 in Advanced Powder Technology
Verified
Journal Article
Closed access
YLYanna Liu
Yanna Liu
WXWencan Xiao
Wencan Xiao
SXSONG XIAO
SONG XIAO

5 April 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
JZJing Zhang
Jing Zhang
TZTing Zhang
Ting Zhang
GGGuiwen Guan
Guiwen Guan
JWJiyun Wen
Jiyun Wen
CCChia-Chen Chen
Chia-Chen Chen
Xiangmei  ChenXiangmei Chen
Xiangmei Chen

1 July 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
HSHanjun Sun
Hanjun Sun
PLPing Li
Ping Li
HSHai Su
Hai Su
WWWenying Wang
Wenying Wang
JWJiwei Wang
Jiwei Wang
XCXiaoshu Cheng
Xiaoshu Cheng